FDA Warns Approval Of BioDelivery's Fentanyl Product Onsolis Is One Of A Kind
This article was originally published in The Pink Sheet Daily
Executive Summary
Onsolis' REMS is no template for long-acting opiates under the agency's classwide requirement, FDA says.
You may also be interested in...
Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program
Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.
Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program
Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.
Fentora Expansion Awaits REMS Evaluation
“Complete response” letter calls for Cephalon to “demonstrate” that risk management works before Fentora can add new indication.